RGNX has been in the news 321% more than usual
Mar 03, 2026, 9:33 PM
-0.58%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
RGNX has been in the news recently: Robbins LLP has announced a class action lawsuit for REGENXBIO, Inc. investors who purchased shares between February 9, 2022, and January 27, 2026, in light of safety concerns and a 17.8% decline in stock value. Additionally, shareholders are reminded by the Rosen Law Firm of an April 14, 2026 deadline to register as lead plaintiffs in this potential class action.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.